Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.46 |
| ▸ | MAPT | P10636 | 6/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | MAOA | P21397 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 4/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.44 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.43 |
| ▸ | KDM4A | O75164 | 1/20 | 0.43 |
| ▸ | CASP1 | P29466 | 1/20 | 0.43 |
| ▸ | CASP7 | P55210 | 1/20 | 0.43 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.39 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2778058 | 0.89 | ALDH1A1 (0.40) | KDM4EMAPTALDH1A1GAAMAOA | |
| SCHEMBL9448317 | 0.81 | KDM4E (0.43) | KDM4EMAPTMAPK1HSD17B10MEN1 | |
| SCHEMBL5981019 | 0.78 | MPO (0.48) | KDM4EMAPTALDH1A1MAOAABCB1 | |
| SCHEMBL8791849 | 0.78 | MPO (0.59) | KDM4EMAPTALDH1A1GAAMAPK1 | |
| SCHEMBL21360714 | 0.75 | MAOA (0.56) | KDM4EMAPTALDH1A1GAAMAOA | |
| SCHEMBL12801524 | 0.74 | MAOA (0.50) | KDM4EMAPTALDH1A1GAAMAOA | |
| SCHEMBL17028333 | 0.72 | HTR2A (0.42) | — | |
| SCHEMBL7384168 | 0.71 | GRM5 (0.43) | KDM4EMAPTALDH1A1GAAMAOA | |
| SCHEMBL26546690 | 0.71 | ALDH1A1 (0.47) | KDM4EMAPTALDH1A1GAAMAOA | |
| SCHEMBL9448055 | 0.71 | SIGMAR1 (0.41) | KDM4EMAPTALDH1A1ABCB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240000950-A1 | THERAPEUTIC CURE-PRO COMPOUNDS FOR TARGETED DEGRADATION OF BET DOMAIN PROTEINS, AND METHODS OF MAKING AND USING THEM | CORNELL UNIVERSITY | 2024-01-04 | — | — | US | disclosed |
| US-20230285570-A1 | THERAPEUTICALLY USEFUL CURE-PRO MOLECULES FOR E3 LIGASE MEDIATED DEGRADATION OF PROTEINS, AND METHODS OF MAKING AND USING THEM | CORNELL UNIVERSITY | 2023-09-14 | — | — | US | disclosed |
| US-20230285570-A1 | THERAPEUTICALLY USEFUL CURE-PRO MOLECULES FOR E3 LIGASE MEDIATED DEGRADATION OF PROTEINS, AND METHODS OF MAKING AND USING THEM | CORNELL UNIVERSITY | 2023-09-14 | — | — | US | disclosed |
| US-20230285570-A1 | THERAPEUTICALLY USEFUL CURE-PRO MOLECULES FOR E3 LIGASE MEDIATED DEGRADATION OF PROTEINS, AND METHODS OF MAKING AND USING THEM | CORNELL UNIVERSITY | 2023-09-14 | — | — | US | disclosed |
| US-20230277553-A1 | THERAPEUTIC COMPOSITION OF CURE-PRO COMPOUNDS FOR TARGETED DEGRADATION OF BET DOMAIN PROTEINS, AND METHODS OF MAKING AND USAGE | CORNELL UNIVERSITY | 2023-09-07 | — | — | US | disclosed |
| US-20230277553-A1 | THERAPEUTIC COMPOSITION OF CURE-PRO COMPOUNDS FOR TARGETED DEGRADATION OF BET DOMAIN PROTEINS, AND METHODS OF MAKING AND USAGE | CORNELL UNIVERSITY | 2023-09-07 | — | — | US | disclosed |
| US-20230277553-A1 | THERAPEUTIC COMPOSITION OF CURE-PRO COMPOUNDS FOR TARGETED DEGRADATION OF BET DOMAIN PROTEINS, AND METHODS OF MAKING AND USAGE | CORNELL UNIVERSITY | 2023-09-07 | — | — | US | disclosed |
| EP-4192824-A1 | THERAPEUTIC COMPOSITION OF CURE-PRO COMPOUNDS FOR TARGETED DEGRADATION OF BET DOMAIN PROTEINS, AND METHODS OF MAKING AND USAGE | Cornell University (US) | 2023-06-14 | — | — | EP | disclosed |
| EP-4192504-A2 | THERAPEUTIC CURE-PRO COMPOUNDS FOR TARGETED DEGRADATION OF BET DOMAIN PROTEINS, AND METHODS OF MAKING AND USING THEM | Cornell University (US) | 2023-06-14 | — | — | EP | disclosed |
| EP-4192825-A2 | THERAPEUTICALLY USEFUL CURE-PRO MOLECULES FOR E3 LIGASE MEDIATED DEGRADATION OF PROTEINS, AND METHODS OF MAKING AND USING THEM | Cornell University (US) | 2023-06-14 | — | — | EP | disclosed |
| US-9771345-B2 | Coferons and methods of making and using them | CORNELL UNIVERSITY (US) | 2017-09-26 | — | — | US | disclosed |
| US-9771345-B2 | Coferons and methods of making and using them | CORNELL UNIVERSITY (US) | 2017-09-26 | — | — | US | disclosed |
| US-20120295874-A1 | COFERONS AND METHODS OF MAKING AND USING THEM | CORNELL UNIVERSITY (US) | 2012-11-22 | — | — | US | disclosed |
| US-20120295874-A1 | COFERONS AND METHODS OF MAKING AND USING THEM | CORNELL UNIVERSITY (US) | 2012-11-22 | — | — | US | disclosed |
| US-20120295874-A1 | COFERONS AND METHODS OF MAKING AND USING THEM | CORNELL UNIVERSITY (US) | 2012-11-22 | — | — | US | disclosed |
| EP-2485678-A1 | COFERONS AND METHODS OF MAKING AND USING THEM | Cornell University (US) | 2012-08-15 | — | — | EP | disclosed |
| WO-2011043817-A1 | COFERONS AND METHODS OF MAKING AND USING THEM | CORNELL UNIVERSITY (US) | 2011-04-14 | — | — | WO | disclosed |
| WO-2011043817-A1 | COFERONS AND METHODS OF MAKING AND USING THEM | CORNELL UNIVERSITY (US) | 2011-04-14 | — | — | WO | disclosed |
| EP-0095666-B1 | TETRAHYDRO-BENZO(E) ISOINDOLINES | ABBOTT LABORATORIES (US) | 1989-01-18 | — | — | EP | disclosed |
| EP-0095666-A2 | Tetrahydro-benzo(e) isoindolines | ABBOTT LABORATORIES (US) | 1983-12-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120295874-A1 | COFERONS AND METHODS OF MAKING AND USING THEM | MYOF, FTH1, HCCS | KDM4E 4500/4885MAPT 2941/4885ALDH1A1 2127/4885 |
| US-20240000950-A1 | THERAPEUTIC CURE-PRO COMPOUNDS FOR TARGETED DEGRADATION OF BET DOMAIN PROTEINS, AND METHODS OF MAKING AND USING THEM | BET1, BRD4, BAZ2A | KDM4E 325/4885MAPT 3174/4885ALDH1A1 4266/4885 |
| US-20230285570-A1 | THERAPEUTICALLY USEFUL CURE-PRO MOLECULES FOR E3 LIGASE MEDIATED DEGRADATION OF PROTEINS, AND METHODS OF MAKING AND USING THEM | XIAP, CUL4A, CUL1 | KDM4E 597/4885MAPT 3111/4885ALDH1A1 2592/4885 |
| US-20230277553-A1 | THERAPEUTIC COMPOSITION OF CURE-PRO COMPOUNDS FOR TARGETED DEGRADATION OF BET DOMAIN PROTEINS, AND METHODS OF MAKING AND USAGE | BET1, BRD4, PHKB | KDM4E 437/4885MAPT 2862/4885ALDH1A1 4450/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.